NCT00717262

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

A Phase 1, Double-Blind, Placebo Controlled, Repeat-Dose Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (estimated)
• Sponsor: HemaQuest Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, activity and pharmacokinetics of a new investigational drug (HQK-1001) in healthy human volunteers. This study will also evaluate if there are differences in these parameters when HQK-1001 is administered in a fed versus a fasted state.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	HQK-1001	HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
DRUG	placebo	Matching placebo capsules administered once a day, orally, for 14 days.

Timeline

• Start date: 2008-05-01
• Primary completion: 2008-08-01
• Completion: 2008-09-01
• First posted: 2008-07-17
• Last updated: 2009-01-16

Locations

1 site across 1 country: United States